Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEON-2: Davoceticept + Pembrolizumab in Advanced Malignancies
NCT04920383Phase 1Terminated
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Jun 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of davoceticept in solid tumor (advanced stage) and lymphoma, sponsored by Alpine Immune Sciences, Inc. Primary endpoints: Dose-limiting Toxicities up to 6 weeks, Adverse Events and 1 more. Started Jun 2021; status: terminated.
02
Drugs
davoceticept
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT04920383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920383.